Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties

1. An implantable medical device, comprising:

a device body;

an optional primer layer disposed over the device body;

a drug reservoir layer disposed over the device body or the primer layer, if opted,

wherein the drug reservoir layer comprises one or more therapeutic agents and poly(acrylate) or poly(methacrylate) of the formula:

wherein:

m =0.005 to 0.90;

n =0.10 to 0.995;

m +n =1;

x=65 to 6960;

R 1 and R 2 are independently selected from the group consisting, of H and methyl;

Hydrocarbon Group is selected from the group consisting of an unsatureated or saturated, branched or straight chain C 1 to C 16 aliphatic, a cycloaliphatic, and an aromatic moiety; and

Polar Group is selected from the group consisting of

and

a topcoat layer disposed as an outermost layer over the drug reservoir layer,

wherein the topcoat layer comprises a phosphoryl choline acrylate polymer.

2. The implantable medical device of claim 1 , wherein the device is a stent.

3. The implantable medical device of claim 1 , wherein the phosphoryl choline acrylate polymer comprises poly(2-(methacryloyloxyethyl)-2-(trimethylammoniumethyl)-phosphate, inner salt)-co-(n-dodecylmethacrylate)-co-(hydroxypropylmethacrylate)-co-(3-trimethoxysilyl)propylmethacrylate).

4. The implantable medical device of claim 3 , wherein the (2-(methacryloyloxyethyl)-2-(trimethylammoniumethyl)-phosphate, inner salt)/(n-dodecylmethacrylate)/ (hydroxypropylmethacrylate)/(3-trimethoxysilyl)propylmethacrylate) constitutional unit wt/wt ratio is about 28.8:50.7:15.3:5.3.

5. The implantable medical device of claim 1 , wherein the phosphoryl choline acrylate polymer is substantially amorphous.

6. A method of treating a vascular disease, comprising:

deploying in the vasculature of a patient in need thereof an implantable medical device according to claim 1 .

7. The method of claim 6 , wherein the device is a stent.

8. The method of claim 6 , wherein for the device, the phosphoryl choline acrylate polymer comprises poly(2-(methacryloyloxyethyl)-2-(trimethylammoniumethyl)-phosphate, inner salt)-co-(n-dodecylmethacrylate)-co-(hydroxypropylmethacrylate)-co-(3-trimethoxysilyl)propylmethacrylate).

9. The method of claim 8 , wherein the (2-(methacryloyloxyethyl)-2-(trimethylammoniumethyl)-phosphate, inner salt)/(n-dodecylmethacrylate)/ (hydroxypropylmethacrylate)/(3-trimethoxysilyl)-propylmethacrylate) constitutional unit wt/wt ratio is about 28.8:50.7:15.3:5.3.

10. The method of claim 6 , wherein for the device, the phosphoryl choline acrylate polymer is substantially amorphous.

11. The method of claim 6 , wherein the vascular disease is atherosclerosis.

12. The method of claim 6 , wherein the vascular disease is restenosis.

13. The method of claim 6 , wherein the vascular disease is vulnerable plaque.

14. The method of claim 6 , wherein the vascular disease is peripheral vascular disease.

15. The method of claim 6 , wherein the vascular disease is late stent thrombosis.